The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! The stock increased 4.98% or $0.65 on October 3, hitting $13.7. About 334,025 shares traded hands or 23.63% up from the average. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 117.50% since February 29, 2016 and is uptrending. It has outperformed by 105.28% the S&P500.
The move comes after 5 months positive chart setup for the $128.00M company. It was reported on Oct, 4 by Barchart.com. We have $36.85 PT which if reached, will make NASDAQ:ZYNE worth $216.32 million more.
Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 9. They expect $-0.60 EPS, down 3.45% or $0.02 from last year’s $-0.58 per share. After $-0.70 actual EPS reported by Zynerba Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -14.29% EPS growth.
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage
Out of 4 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 6 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Oppenheimer maintained Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Thursday, November 12 with “Outperform” rating. The rating was initiated by Canaccord Genuity with “Buy” on Monday, September 14. Jefferies initiated the stock with “Buy” rating in Monday, August 31 report. The firm has “Outperform” rating by Oppenheimer given on Tuesday, September 8. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has “Overweight” rating given on Monday, August 31 by Piper Jaffray.
According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”
More news for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) were recently published by: Quotes.Wsj.com, which released: “News Zynerba Pharmaceuticals Inc.ZYNE” on July 31, 2015. Benzinga.com‘s article titled: “GW Pharma’s Epidiloex Data Is Good News For Zynerba” and published on September 26, 2016 is yet another important article.
ZYNE Company Profile
Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.